MRNA-4157 is under clinical development by Moderna and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MRNA-4157’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
mRNA-4157 is under development for the treatment of solid tumors including metastatic melanoma, non-small cell lung cancer, small-cell lung cancer, head and neck squamous cell carcinoma, bladder urothelial carcinoma, head and neck squamous cell carcinoma including oral cavity cancer, laryngeal cancer, oropharyngeal cancer, hypopharyngeal cancer and colorectal cancer. It is administered through intramuscular route. The therapeutic candidate is developed by using mRNA vaccine technology, which enables the delivery of mRNA encoding for peptides containing personalized neoantigens to specific tumors and LNP technology. It was also under development for the treatment of stomach adenocarcinoma, esophageal adenocarcinoma and endometrial cancer.
Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-4157’s drug-specific PTSR and LoA scores, buy the report here.